环戊羧酸,2-氨基-,甲基酯,(1S,2R)- | 362485-20-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 环戊羧酸,2-氨基-,甲基酯,(1S,2R)-
• 英文名称: methyl (1S,2R)-2-aminocyclopentane-1-carboxylate
• 英文别名: (1S,2R)-Methyl 2-aminocyclopentanecarboxylate
• CAS: 362485-20-9
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: RGXCCQQWSIEIEF-NTSWFWBYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  环戊羧酸,2-氨基-,甲基酯,(1S,2R)- 、 8-bromo-3,7-dimethyl-1-(4-(trifluoromethyl)benzyl)-3,7-dihydro-1H-purine-2,6-dione 在 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 methyl (1S,2R)-2-[(3,7-dimethyl-2,6-dioxo-1-{[4-(trifluoromethyl)phenyl]methyl}-2,3,6,7-tetrahydro-1H-purin-8-yl)amino]cyclopentane-1-carboxylate
  参考文献：
  名称：

  [EN] CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF
  [FR] INHIBITEURS DE CAFÉINE DE MTHFD2 ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物、其组合物以及使用方法。

  公开号：

  WO2017106352A1
• 作为产物：
  描述：

  (1R.2S)-2-(Boc-氨基)环戊烷甲酸 在 盐酸 作用下， 以 1,4-二氧六环 、 乙醚 为溶剂， 反应 2.0h， 生成 环戊羧酸,2-氨基-,甲基酯,(1S,2R)-
  参考文献：
  名称：

  Probing a molecular model of taste utilizing peptidomimetic stereoisomers of 2-aminocyclopentanecarboxylic acid methyl ester

  摘要：

  On the basis of the preferred conformations of L-aspartyl dipeptide derivatives containing alpha-amino acids at the second position and their retro-inverso analogues deduced by a combination of X-ray crystallography, H-1 NMR spectroscopy, and molecular mechanics calculations, we have proposed a model describing the molecular array required for the sweet taste. The conformation of a sweet molecule is described as possessing an "L shape", with the AH (proton donor) and B (proton acceptor) zwitterionic ring of the aspartyl moiety forming the stem, and the hydrophobic group X forming the base of the "L". Planarity of the molecule in the x and y dimensions is critical for sweet taste. Substantial deviation from this plane into negative z dimension is correlated with bitter taste while other deviations lead to tasteless molecules. To examine the model, the preferred conformations for a series of L-aspartyl dipeptides containing a 2-aminocyclopentanecarboxylic acid (2-Ac5c) residue at the second position were calculated using molecular mechanics. The peptidomimetic 2-Ac5c residue is a beta-amino acid with two chiral centers, resulting in four isomers [trans-(1S,2S)-2-Ac5c, trans-(1R,2R)-2-Ac5c, cis-(1R,2S)-2-Ac5c, and cis-(1S,2R)-2-Ac5c]. Two stereoisomers, L-aspartyl-trans-(1R,2R)-2-aminocyclopentanecarboxylic acid methyl ester [Asp-trans-(1R,2R)-2-Ac5c-OMe] and L-aspartyl-cis-(1S,2R)-2-aminocyclopentanecarboxylic acid methyl ester [Asp-cis-(1S,2R)-2-Ac5c-OMe], prefer the L-shape conformations and are thus predicted to be sweet. For L-aspartyl-trans-(1S,2S)-2-aminocyclopentanecarboxylic acid methyl ester [Asp-trans-(1S,2S)-2-Ac5c-OMe], the methyl ester group projects behind the stem of the L shape, producing a large negative z component and is predicted to exhibit a bitter taste. The calculations predict that L-aspartyl-cis-(1R,2S)-2-aminocyclopentanecarboxylic acid methyl ester [Asp-cis-(1R,2S)-2-Ac5c-OMe] will be tasteless. In this investigation, in addition to the calculations, we report the synthesis and experimental conformational analysis of the four stereoisomers of Asp-2-Ac5c-OMe. The absolute configurations of the 2-Ac5c residues were assigned by X-ray diffraction studies and by correlating optical rotation and enantiomeric excess values. These studies fully confirm our configurational assignments of the stereoisomers of Asp-2-Ac5c-OMe. Thus, the structure-taste relationships observed for the new class of L-aspartyl taste ligands containing the 2-Ac5c beta-amino acid methyl esters in the second position agree with and strengthen our model for the sweet and bitter taste responses.

  DOI：

  10.1021/jo00023a033

文献信息

• Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
  申请人：——

  公开号：US20030139388A1

  公开（公告）日：2003-07-24

  The present application describes novel cyclic hydroxamic acids of formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR 1 , and S(O) p , and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same.

  本申请描述了新型的公式I:1的环式羟羧酸，或其药用盐形式，其中环B是一个包含0-2个来自O、N、NR1和S(O)p的杂原子以及0-1个羰基的5-7元环系统，其他变量在本说明书中有定义，这些化合物可作为基质金属蛋白酶（MMP）、TNF-α转化酶（TACE）、聚集素酶或其组合的抑制剂，包含这些化合物的药物组合物，以及使用这些化合物的方法。
• ORNITHINE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP2141147A1

  公开（公告）日：2010-01-06

  Provided is a compound which is useful as a therapeutic agent for chronic renal insufficiency and a therapeutic agent for diabetic nephropathy. The present inventors have made extensive studies on an ornithine derivative having an antagonistic action against an EP4 receptor, and as a result, they have found that by introducing cycloalkanediyl at a C terminal of the ornithine part of the compound of the present invention, the physicochemical properties such as solubility, and the like can be improved, thereby giving further preferred properties as a pharmaceutical. Therefore, they have completed the present invention. The compound of the present invention exhibits a good antagonistic action against an EP4 receptor, and thus, it is useful as a therapeutic agent for chronic renal insufficiency and diabetic nephropathy.

  提供了一种化合物，可用作慢性肾功能不全的治疗剂和糖尿病肾病的治疗剂。目前的发明人对具有对EP4受体拮抗作用的鸟氨酸衍生物进行了广泛研究，结果发现通过在目前发明的化合物的鸟氨酸部分的C末端引入环烷基，可以改善物理化学性质，如溶解性等，从而赋予其作为药物的更优越性质。因此，他们完成了这项发明。目前发明的化合物对EP4受体表现出良好的拮抗作用，因此，它可用作慢性肾功能不全和糖尿病肾病的治疗剂。
• Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives
  申请人：Marcin R. Lawrence

  公开号：US20050113442A1

  公开（公告）日：2005-05-26

  A series of N-cycloalkylcarboxamide derivatives of N-benzyl benzenesulfonamides of Formula I are described. The compounds inhibit β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions characterized by aberrant extracellular deposition of β-amyloid. Pharmaceutical compositions and methods of treatment using these compounds are also disclosed.

  本文描述了一系列N-环烷基羧酰胺衍生物的N-苯甲基苯磺酰胺化合物，其化学式为I。这些化合物抑制β-淀粉样肽（β-AP）的产生，可用于治疗阿尔茨海默病和其他由β-淀粉样蛋白异常细胞外沉积所特征的疾病。还公开了使用这些化合物的药物组合物和治疗方法。
• Novel lactam metalloprotease inhibitors
  申请人：——

  公开号：US20020042398A1

  公开（公告）日：2002-04-11

  The present application describes novel lactams and derivatives thereof of formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring B is a 4-8 membered cyclic amide comprising 0-3 additional heteroatoms selected from N, O, and S, which are useful as metalloprotease inhibitors.

  本申请描述了具有以下结构的新型内酰胺及其衍生物：1或其药用盐形式，其中环B是一个由0-3个额外的杂原子N、O和S选择的4-8元环酰胺，这些化合物可用作金属蛋白酶抑制剂。
• Potent, exceptionally selective, orally bioavailable inhibitors of TNF-α Converting Enzyme (TACE): Novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1′ substituents
  作者：Gregory R. Ott、Naoyuki Asakawa、Zhonghui Lu、Rajan Anand、Rui-Qin Liu、Maryanne B. Covington、Krishna Vaddi、Mingxin Qian、Robert C. Newton、David D. Christ、James M. Trzaskos、James J.-W. Duan

  DOI：10.1016/j.bmcl.2008.01.075

  日期：2008.3

  Novel ((2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamides were found to be excellent P1' substituents in conjunction with unique constrained beta-amino hydroxamic acid scaffolds for the discovery of potent selective inhibitors of TNF-alpha Converting Enzyme (TACE). Optimized examples proved potent for TACE, exceptionally selective over a wide panel of MMP and ADAM proteases, potent in the suppression

  发现新型（（2-取代的-1H-苯并[d]咪唑-1-基）甲基）苯甲酰胺是出色的P1'取代基，结合独特的受约束的β-氨基异羟肟酸支架，可发现有效的TNF选择性抑制剂-alpha转换酶（TACE）。优化的实例证明了对TACE的有效作用，对多种MMP和ADAM蛋白酶具有极高的选择性，对抑制人全血中LPS诱导的TNF-α具有有效作用，并且具有口服生物利用度。